National Health (Price and Special Patient Contribution) Amendment Determination 2012 (No. 3) (No. PB 28 of 2012)

Administered by Department of Health, Disability and Ageing

Legislation au F2012L00936 Not in force Legislative Instrument

Legislation content

EXPLANATORY STATEMENT

National Health Act 1953

National Health (Price and Special Patient Contribution)

Amendment Determination 2012 (No. 3)

PB 28 of 2012

 

Authority

This legislative instrument, made under section 85B of the National Health Act 1953 (the Act) amends the National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010) (the Principal Determination).

The Principal Determination provides for price determinations in relation to brands of pharmaceutical items for which the Minister and the responsible person have not been able to make a price agreement. It also provides for the circumstances in which the Commonwealth will pay the special patient contribution resulting from these price determinations.

Purpose

The Act provides for the Minister and the responsible person to agree a price that is taken to be the appropriate maximum price for sales of a brand of a pharmaceutical item to approved pharmacists (section 85AD). Section 85B of the Act applies if the Minister and the responsible person have been unable to reach an agreement.

Subsection 85B(2) provides that the Minister may determine an amount that is taken to be the appropriate maximum price for sales of a brand of a pharmaceutical item to approved pharmacists. This is termed the ‘Determined Price’.

Subsection 85B(3) provides that the Minister may determine an amount that is taken to be the price claimed by the responsible person as the appropriate maximum price for sales of the brand of the pharmaceutical item to approved pharmacists. This is termed the ‘Claimed Price’.

The Determined Price is the approved price to pharmacists (subsection 98B(3) of the Act) and is used as the basis for working out the Commonwealth price for the brand of the pharmaceutical item (subsection 98B(2) of the Act). Approved pharmacists are entitled to payment from the Commonwealth equal to the Commonwealth price less the applicable patient co-payment (section 99 of the Act).

The difference between the responsible person’s Commonwealth price (ie, the price that would be the Commonwealth price if the responsible person’s claimed price had become the approved price to pharmacists) and the Commonwealth price for the brand is defined in subsection 85B(4) of the Act as the special patient contribution.  An approved pharmacist may charge a patient an amount equal to the special patient contribution, in addition to any applicable patient co-payment (subsection 87(2A) of the Act).

Subsection 85B(5) of the Act provides that the Minister may determine the circumstances in which the Commonwealth, rather than the patient, is to pay the special patient contribution for a brand of a pharmaceutical item.

 

 

This instrument (the Amending Determination) amends the Principal Determination by: adding one new brand premium and reflecting for plain English reasons the price change and decrease to multiple existing brand premiums which took legal effect on 1 April 2012 due to price disclosure reductions.

Consultation

The Amending Determination affects certain responsible persons with medicines listed on the PBS.  Before a pharmaceutical benefit is listed on the PBS, and from time to time thereafter, price negotiations occur between the responsible person and the Minister for the purpose of reaching a price agreement for section 85AD of the Act.  If the Minister and the responsible person cannot agree on a price, further consultation occurs with the responsible person, and thereafter the Minister determines the price that will be the approved price to pharmacists for the brand.  The Minister also determines the corresponding price claimed by the responsible person which is used to calculate the special patient contribution that will apply to the brand. 

A provision by provision description of the Amending Determination is contained in Attachment 1.

The Amending Determination commences on 1 May 2012.

This instrument is a legislative instrument for the purposes of the Legislative Instruments Act 2003.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ATTACHMENT 1

 

PROVISION BY PROVISION DESCRIPTION OF THE NATIONAL HEALTH (PRICE AND SPECIAL PATIENT CONTRIBUTION) AMENDMENT DETERMINATION 2012 (No.3)

Section 1   Name of Instrument

This section provides that this Amending Determination is the National Health (Price and Special Patient Contribution) Amendment Determination 2012 (No. 3) and may also be cited as PB 28 of 2012.

Section 2   Commencement

This section provides that the Amendment Determination commences on                    1 May 2012. 

Section 3   Amendment of PB 109 of 2010

This section provides that Schedule 1 of the Amending Determination amend the determination under section 85B of the Act, the National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010).

Schedule 1    Amendments commencing 1 May 2012

Schedule 1 sets out the amendments to the Principal Determination which commence on 1 May 2012 (Attachment 2).

 

 

 

 

 

 

 

 

 

 

 

 

 


ATTACHMENT 2

 

 

SUMMARY OF CHANGES

SCHEDULE 1

 

Brand with a new brand premium

Bleomycin

Powder for injection containing bleomycin sulphate 15,000 I.U.

Bleo 15K

 

Brands with a price change and a decreased brand premium

Alendronic Acid

Tablet 70 mg (as alendronate sodium)

Fosamax Once Weekly

Alprazolam

Tablet 250 micrograms

Xanax

 

Tablet 500 micrograms

Xanax

 

Tablet 1 mg

Xanax

 

Tablet 2 mg

Xanax Tri-Score

Amlodipine

Tablet 5 mg (as besylate)

Norvasc

 

Tablet 10 mg (as besylate)

Norvasc

Amoxycillin

Tablet 1 g (as trihydrate)

Maxamox

 

Capsule 250 mg (as trihydrate)

Amoxil

 

Capsule 500 mg (as trihydrate)

Amoxil

 

Powder for oral suspension 125 mg (as trihydrate) per 5 mL, 100 mL

Amoxil

 

Powder for oral suspension 250 mg (as trihydrate) per 5 mL, 100 mL

Amoxil Forte

Amoxycillin with Clavulanic Acid

Tablet containing 500 mg amoxycillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate)

Augmentin Duo

 

Tablet containing 875 mg amoxycillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate)

Augmentin Duo forte

 

Powder for oral suspension containing 125 mg amoxycillin (as trihydrate) with 31.25 mg clavulanic acid (as potassium clavulanate ) per 5 mL, 75 mL

Augmentin

 

Powder for oral suspension containing 400 mg amoxycillin (as trihydrate) with 57 mg clavulanic acid (as potassium clavulaante) per mL, 60 mL

Augmentin Duo 400

Atenolol

Tablet 50 mg

Tenormin

Baclofen

Tablet 10 mg

Lioresal 10

 

Tablet 25 mg

Lioresal 25

Captopril

Tablet 25 mg

Capoten

 

Tablet 50 mg`

Capoten

Cefaclor

Tablet (sustained release) 375 mg (as monohydrate)

Ceclor CD

 

Powder for oral suspension 125 mg (as monohydrate) per 5 mL, 100 mL

Ceclor

 

Powder for oral suspension 250 mg (as monohydrate) per 5 mL, 75 mL

Ceclor

Cephalexin

Capsule 250 mg (anhydrous)

Keflex

 

Capsule 500 mg (anhydrous)

Keflex

 

Granules for oral suspension 125 mg per 5 mL, 100 mL

Keflex

 

Granules for oral suspension 250 mg per 5 mL, 100 mL

Keflex

Ciprofloxacin

Tablet 250 mg (as hydrochloride)

Ciproxin 250

 

Tablet 500 mg (as hydrochloride)

Ciproxin 500

 

Tablet 750 mg (as hydrochloride)

Ciproxin 750

Citalopram

Tablet 20 mg (as hydrobromide)

Cipramil

Clarithromycin

Tablet 250 mg

Klacid

Clomipramine

Tablet containing clomipramine hydrochloride 25 mg

Anafranil 25

Codeine with Paracetamol

Tablet containing codeine phosphate 30 mg with paracetamol 500 mg

Panadeine Forte

Enalapril

Tablet containing enalapril maleate 5 mg

Renitec M

 

Tablet containing enalapril maleate 10 mg

Renitec

 

Tablet containing enalapril maleate 20 mg

Renitec 20

Famotidine

Tablet 40 mg

Pepcidine

Felodipine

Tablet 2.5 mg (extended release)

Plendil ER

 

Tablet 5 mg (extended release)

Plendil ER

 

Tablet 10 mg (extended release)

Plendil ER

Fluoxetine

Tablet, dispersible, 20 mg (as hydrochloride)

Prozac Tab

 

Capsule 20 mg (as hydrochloride)

Prozac 20

Fluvoxamine

Tablet containing fluvoxamine maleate 50 mg

Luvox

 

Tablet containing fluvoxamine maleate 100 mg

Luvox

Gabapentin

Capsule 100 mg

Neurontin

 

Capsule 300 mg

Neurontin

 

Capsule 400 mg

Neurontin

 

Tablet 600 mg

Neurontin

 

Tablet 800 mg

Neurontin

Gemfibrozil

Tablet 600 mg

Lopid

Glimepiride

Tablet 1 mg

Amaryl

 

Tablet 2 mg

Amaryl

 

Tablet 3 mg

Amaryl

 

Tablet 4 mg

Amaryl

Isosorbide Mononitrate

Tablet 60 mg (sustained release)

Imdur Durule

 

Tablet 120 mg (sustained release)

Imdur 120 mg

Isotretinoin

Capsule 20 mg

Roaccutane

Lactulose

Solution BP 3.34 g per 5 mL, 500 mL

Duphalac

Lamotrigine

Tablet 5 mg

Lamictal

 

Tablet 25 mg

Lamictal

 

Tablet 50 mg

Lamictal

 

Tablet 100 mg

Lamictal

 

Tablet 200 mg

Lamictal

Lercanidipine

Tablet containing lercanidipine hydrochloride 10 mg

Zanidip

 

Tablet containing lercanidipine hydrochloride 20 mg

Zanidip

Lisinopril

Tablet 5 mg

Zestril

 

 

Prinivil 5

 

Tablet 10 mg

Zestril

 

 

Prinivil 10

 

Tablet 20 mg

Zestril

 

 

Prinivil 20

Metformin

Tablet containing metformin hydrochloride 500 mg

Glucophage

 

 

Diabex

 

Tablet containing metformin hydrochloride 850 mg

Glucophage

 

 

Diabex 850

 

Tablet containing metformin hydrochloride 1 g

Diabex 1000

Metoprolol

Tablet containing metoprolol tartrate 50 mg

Lopresor 50

 

 

Betaloc

 

Tablet containing metoprolol tartrate 100 mg

Lopresor 100

 

 

Betaloc

Mirtazapine

Tablet 30 mg

Avanza

 

Tablet 45 mg

Avanza

Moclobemide

Tablet 150 mg

Aurorix

 

Tablet 300 mg

Aurorix 300 mg

Nifedipine

Tablet 10 mg

Adalat 10

 

Tablet 20 mg

Adalat 20

 

Tablet 30 mg  (controlled release)

Adalat Oros 30

 

Tablet 60 mg (controlled release)

Adalat Oros 60

Norfloxacin

Tablet 400 mg

Noroxin

Omeprazole

Tablet 20 mg (as magnesium)

Losec Tablets

Paroxetine

Tablet 20 mg (as hydrochloride)

Aropax

Pravastatin

Tablet containing pravastatin sodium 10 mg

Pravachol

 

Tablet containing pravastatin sodium 20 mg

Pravachol

 

Tablet containing pravastatin sodium 40 mg

Pravachol

 

Tablet containing pravastatin sodium 80 mg

Pravachol

Quinapril

Tablet 5 mg (as hydrochloride)

Accupril

 

Tablet 10 mg (as hydrochloride)

Accupril

 

Tablet 20 mg (as hydrochloride)

Accupril

Roxithromycin

Tablet 150 mg

Rulide

 

Tablet 300 mg

Rulide

Sertraline

Tablet 50 mg (as hydrochloride)

Zoloft

 

Tablet 100 mg (as hydrochloride)

Zoloft

Simvastatin

Tablet 5 mg

Zocor

 

Tablet 10 mg

Lipex 10

 

 

Zocor

 

Tablet 20 mg

Lipex 20

 

 

Zocor

 

Tablet 40 mg

Lipex 40

 

 

Zocor

 

Tablet 80 mg

Lipex 80

 

 

Zocor

Sotalol

Tablet containing sotalol hydrochloride 80 mg

Sotacor

 

Tablet containing sotalol hydrochloride 160 mg

Sotacor

Temazepam

Tablet 10 mg

Normison

Tramadol

Capsule containing tramadol hydrochloride 50 mg

Tramal

 

Tablet (sustained release) containing tramadol hydrochloride 100 mg

Tramal SR 100

 

Tablet (sustained release) containing tramadol hydrochloride 150 mg

Tramal SR 150

 

Tablet (sustained release) containing tramadol hydrochloride 200 mg

Tramal SR 200

Trandolapril

Capsule 500 micrograms

Gopten

 

Capsule 1 mg

Gopten

 

Capsule 2 mg

Gopten

 

Capsule 4 mg

Gopten

 

 

 

Interactions

Authorises

All Versions

Sourced from the Federal Register of Legislation at 26 August 2026. For the latest information on Australian Government law please go to https://www.legislation.gov.au.